Logo
x

Search

Subscribe Now

Relapsing

Janssen's Ponvory (ponesimod) Receives the US FDA's Approval for the Treatment of Relapsing Multiple Sclerosis

Janssen's Ponvory (ponesimod) Receives the US FDA's Approval for the Treatment of Relapsing Multiple Sclerosis

  • March 22, 2021
Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

  • December 15, 2020
Novartis' Kesimpta (ofatumumab) Receives the US FDA's Approval as the First Self-Administered Therapy for Relapsing Multiple Sclerosis

Novartis' Kesimpta (ofatumumab) Receives the US FDA's Approval as the First Self-Administered Therapy for Relapsing Multiple Scler...

  • August 21, 2020
Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

  • August 3, 2020
Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple Sclerosis

Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple S...

  • May 28, 2020
BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Act...

  • March 30, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.